3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Completed
2
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
72
Breast Neoplasms
63
Neoplasms
59
Leukemia, Myeloid, Acute
59
Multiple Myeloma
53
Colorectal Neoplasms
48
Lymphoma
46
Recurrence
45
Carcinoma, Hepatocellular
45
Stomach Neoplasms
43
Pancreatic Neoplasms
40
Neoplasm Metastasis
39
Prostatic Neoplasms
34
Melanoma
34
Leukemia
30
Lymphoma, Non-Hodgkin
27
Lymphoma, B-Cell
27
Lung Neoplasms
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Glioblastoma
24
Ovarian Neoplasms
23
Lymphoma, Large B-Cell, Diffuse
21
Esophageal Neoplasms
21
Carcinoma, Renal Cell
20
Myelodysplastic Syndromes
19
Leukemia, Lymphocytic, Chronic, B-Cell
19
Hematologic Neoplasms
19
Colonic Neoplasms
19
Head and Neck Neoplasms
18
Lymphoma, Mantle-Cell
17
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Unknown
×
Gastro-enteropancreatic neuroendocrine tumor
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled